Esophageal cancer is a very serious disease, and as with other cancers, the sooner it is diagnosed, the better the patient’s prognosis will be. Unfortunately, in many cases early-stage esophageal cancer has no symptom or symptoms that are attributed to GERD and acid reflux. For that reason, the Florida Hospital Cancer Institute, in partnership with the Florida Hospital Digestive Health Center, provides a comprehensive Esophageal Cancer Program that focuses on early diagnosis and prevention. These are the keys to saving lives.
We offer patients a multidisciplinary team of specialists, including gastroenterologists, surgical oncologists, medical oncologists, radiation oncologists, therapeutic endoscopists, radiologists and a dedicated thoracic cancer care coordinator. These experts work together to create a specialized treatment plan for each patient.
In addition, Florida Hospital Orlando is a leader in treating Barrett’s esophagus, a condition affecting the lining of the esophagus that affects more than 3 million adults in the United States. While this condition itself does not produce symptoms, the acid reflux generally associated with it can lead to heartburn. Though heartburn is most often seen as just a nuisance, it could also be a warning sign. People with Barrett’s esophagus are at increased risk of developing esophageal cancer.
Our gastroenterologists use the cutting-edge HALO procedure to manage Barrett’s esophagus and prevent esophageal cancer. The HALO procedure is an ablation technique used for pre-cancerous Barrett’s esophagi. Along with our gastroenterologists that are specialized in this condition, Florida Hospital Cancer Institute is also home to a certified Thoracic Medical Oncologist that works closely with the multi-disciplinary care team if any cancer treatment or prevention is needed.
The Florida Hospital Cancer Institute is accredited by several national cancer organizations for their quality, outcomes and comprehensive care. FHCI is accredited by the American College of Surgeons’ Commission on Cancer (COC) and the Quality Oncology Practice Initiative (QOPI). Most recently, our Clinical Research Center has been awarded a $2.1 million grant from the National Cancer Institute’s Community Clinical Oncology Program (CCOP), allowing FHCI access to NCI’s prevention, control and treatment trials for cancer treatment and prevention. Learn more about clinical trials and The Lung and Esophageal Cancer Program.
Learn more about Florida Hospital Cancer Institute’s offerings: